BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22846975)

  • 1. The role of integrated 18F-FDG PET-CT as a staging tool for limited-stage small cell lung cancer: a retrospective study.
    Sohn BS; Lee DH; Kim EK; Yoon DH; Kim HO; Ryu JS; Kim SW; Suh C
    Onkologie; 2012; 35(7-8):432-8. PubMed ID: 22846975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
    Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
    J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma.
    Prestwich RJ; Subesinghe M; Gilbert A; Chowdhury FU; Sen M; Scarsbrook AF
    Clin Radiol; 2012 Oct; 67(10):966-75. PubMed ID: 22595082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
    Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
    Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
    Lardinois D; Weder W; Hany TF; Kamel EM; Korom S; Seifert B; von Schulthess GK; Steinert HC
    N Engl J Med; 2003 Jun; 348(25):2500-7. PubMed ID: 12815135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer.
    Arslan N; Tuncel M; Kuzhan O; Alagoz E; Budakoglu B; Ozet A; Ozguven MA
    Ann Nucl Med; 2011 Jul; 25(6):406-13. PubMed ID: 21409347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
    Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
    Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.
    Shen YY; Shiau YC; Wang JJ; Ho ST; Kao CH
    Anticancer Res; 2002; 22(2B):1257-64. PubMed ID: 12168935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of PET staging in limited-stage small-cell lung cancer.
    Xanthopoulos EP; Corradetti MN; Mitra N; Fernandes AT; Kim M; Grover S; Christodouleas JP; Evans TL; Stevenson JP; Langer CJ; Lee TT; Pryma DA; Lin LL; Simone CB; Apisarnthanarax S; Rengan R
    J Thorac Oncol; 2013 Jul; 8(7):899-905. PubMed ID: 23608814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.
    Jhun BW; Lee KJ; Jeon K; Suh GY; Chung MP; Kim H; Kwon OJ; Sun JM; Ahn JS; Ahn MJ; Park K; Choi JY; Lee KS; Han J; Um SW
    Lung Cancer; 2013 Jul; 81(1):65-70. PubMed ID: 23523420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
    Bradley JD; Dehdashti F; Mintun MA; Govindan R; Trinkaus K; Siegel BA
    J Clin Oncol; 2004 Aug; 22(16):3248-54. PubMed ID: 15310768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.